Background: Non-vitamin K antagonist oral anticoagulants (NOAC) have been developed as
alternatives to warfarin. Until recently, the latter was the standard oral anticoagulant for …

Background and Purpose—Several randomized trials and real-world studies have reported
the efficacy and safety of non–vitamin K antagonist oral anticoagulants (NOACs) in Asian …

Background To overcome the several drawbacks of warfarin, non-vitamin K antagonist oral
anticoagulants (NOACs) were developed. Even though randomized controlled trials (RCTs) …

Background and Purpose—The use of vitamin K antagonists (VKAs), the cornerstone
treatment for stroke prevention in patients with atrial fibrillation, is limited by the perceived …

Objective We compared the effectiveness and safety outcomes of non-vitamin K antagonist
oral anticoagulants (NOACs) and warfarin in patients with AF and VHD, as these patients …

We performed this meta-analysis to compare the efficacy and safety of reduced-dose non-
vitamin K antagonist oral anticoagulants (NOACs) versus warfarin in patients with atrial …

Objective To assess the safety (ie, risk of bleeding) and effectiveness (ie, risk of
stroke/systemic embolism (SE)) separately for four non-vitamin K oral anticoagulants …

Aims Non-vitamin K antagonist oral anticoagulants (NOACs) require dose reductions
according to patient or clinical factors for patients with atrial fibrillation (AF). In this meta …

Non–vitamin K antagonist anticoagulants (NOACs) have been used to prevent
thromboembolism in patients with atrial fibrillation (AF) and shown favorable clinical …

Background Although randomized controlled trials (RCTs) indicated that standard dose non–
vitamin K antagonist oral anticoagulants (NOACs) were more compelling, low dose NOACs …